2024 World Conference on Lung Cancer (WCLC) - Posters-P3.13D.09 Prevalence and Prognostic Impact of SEZ6 Expression in a Real-World Cohort of Patients with Small-Cell Lung Cancer

P3.13D.09 Prevalence and Prognostic Impact of SEZ6 Expression in a Real-World Cohort of Patients with Small-Cell Lung Cancer

Back to course

Pdf Summary

The study presented at the World Conference on Lung Cancer in 2024 investigates the prevalence and prognostic value of SEZ6 expression in patients with small cell lung cancer (SCLC). Conducted by a team from AbbVie Inc. and other institutions, the research particularly examines the antibody-drug conjugate ABBV-706, which targets SEZ6 and is being evaluated in clinical trials for advanced solid tumors, including SCLC.<br /><br />Using data from patients treated at the City of Hope National Medical Center, the study analyzes SEZ6 expression's prevalence and stability across different treatment stages. Findings reveal that SEZ6 is a highly prevalent biomarker, detected in 87% of patients via immunohistochemistry (IHC). However, despite its prevalence, SEZ6 was not found to significantly influence clinical outcomes such as progression-free survival (PFS) or response rates, suggesting it does not serve as a prognostic biomarker for SCLC.<br /><br />The study highlights that SEZ6 expression shows similar patterns to other markers like ASCL1 and DLL3 and remains stable over different treatment lines. Furthermore, SEZ6 expression wasn't altered by standard of care frontline treatments. Demographic data indicates a varied sample population comprising predominantly males and white individuals, with a mix of prior treatment histories and smoking statuses.<br /><br />The research concludes that while SEZ6 is prevalent, it lacks prognostic impact on clinical outcomes for SCLC. However, the "real world" data from this cohort could serve as a control in future studies exploring predictive biomarkers for SCLC therapy, providing a foundation for understanding clinical outcomes in single-arm studies.<br /><br />Overall, this study adds important insights into SEZ6's expression in SCLC, pointing out that its primary utility might not be in prognosis but possibly in assisting with other biomarker discovery efforts.

Asset Subtitle

Song Wang

Meta Tag

Speaker Song Wang

Topic SCLC & Neuroendocrine Tumors

Keywords

SEZ6 expression

small cell lung cancer

SCLC

prognostic biomarker

antibody-drug conjugate

ABBV-706

clinical trials

immunohistochemistry

progression-free survival

biomarker discovery